AMYOTROPHIC LATERAL SCLEROSIS (ALS)

This phase 2 trial tests whether the experimental drug VHB937 can slow the decline in function and delay the need for breathing support in people with early-stage ALS. About 251 participants will receive either VHB937 or a placebo for 40 weeks, followed by an open-label extension…

This clinical trial is testing an oral drug called NUZ-001 in 160 people with ALS. Participants take the drug or a placebo daily for 36 weeks. The study measures how the disease progresses using a scale of physical function and survival. The goal is to see if NUZ-001 can slow ALS…

This study tests whether the drug usnoflast can slow the progression of ALS, a severe nerve disease that causes muscle weakness and breathing problems. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily fun…

This early-stage trial tests a single injection of RJK002, a gene therapy, into the spinal fluid of 9 people with ALS. The main goal is to see if it is safe and to find the best dose for future studies. Researchers will also track changes in daily function, but the trial is too s…

This pilot study tests whether using a robotic glove for 20 minutes a day, 5 days a week, can improve quality of life, grip strength, and fine motor control in people with ALS. Five participants will use the glove at home over 8 weeks, with some in-person and telehealth check-ins…

This study uses advanced MRI scans and genetic tests to track how neurodegenerative diseases like frontotemporal dementia and ALS spread across the brain's network. Researchers will follow 645 participants, including patients, family members, and healthy controls, for up to 2 yea…